Henlius Serplulimab Posts 12.4-Month Median OS in U.S. SCLC Study
SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.
ASTRIDE shows a numerical OS edge but no formal superiority test
The hazard ratio was 0.82 (95% CI, 0.56-1.20), at a median follow-up of 14.1 months and a data cutoff of February 18, 2026. The trial was descriptive, with no formal hypothesis testing for superiority or noninferiority planned.
One-year OS rates were 52.4% for serplulimab and 41.4% for atezolizumab. Two-year OS rates were 32.2% and 17.6%, respectively. The serplulimab arm had more patients with liver metastasis (49.5% vs 40.0%).